直播带货潮 国美零售(493.HK)618销售额值得期待

HONG KONG, Jun 17, 2022 - (亚太商讯 via SEAPRWire.com) - 昨日港股活跃,恒指高开200多点,随后开始走弱,昨日收报20845点, 跌462点, 成交量为1584亿元。大盘及新经济等多个板块走弱,而新东方转型的“东方甄选”直播带货引发热点带动教育及电商相关板块逆市增长,留意到国美零售(493.HK)昨日盘中大涨,最高至0.53元,涨幅达41.3%,收盘价涨25.3%报0.47元。受惠于内地家电补贴政策,促进家电更新与夏日带来的新增需求的释放,该市场有望回暖,国美零售亦因此受益。公司拥有数十年的零售经验,并顺势战略调整,旨在构建“线上+线下+供应链+物流+大数据云+共享共建”全零售生态共享平台,以满足家庭消费者高质量、多元化、一站式的全方位需求。作为零售巨头,国美零售的优势一方面在于积淀,统一的供应链体系优于独立经营,规模采购下的产品成本控制,同时拥有遍布中国的近4200家门店,其中包括230多家体验店、1200多家小区店和2700多家新零售店。另一方面,随着消费者网购习惯的形成,线下门店网络已全面数字化,国美在线平台“真快乐APP”实现了门店的在线平移,使得每个门店可服务周边3-5公里的国美社群用户。2021年报显示APP每月活跃用户(MAU)稳定在5,000万以上。而真快乐APP不仅是零售平台,是娱乐化营销,同时兼具社交化和娱乐化,吸引不少明星艺人KOL入驻,兼具抢购商品、直播带货、视频导购等功能。数据显示,“618”活动第一波在6月1日至5日期间,真快乐APP销售额环比5月同期增长接近10%,线下门店总销售额突破5亿元。而目前“618”第二波活动正在如火如荼进行,网购热潮连带各大厂商给予的巨大优惠力度,国美零售有望迎接亮眼的销售额,后市可持续关注。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
Get Me Press Launches an Online PR Agency Focused on Startups and Founders ACN Newswire

Get Me Press Launches an Online PR Agency Focused on Startups and Founders

CHICAGO, IL, Jun 17, 2022 - (ACN Newswire via SEAPRWire.com) - Get Me Press' founders are excited to announce the launch of their online public relations agency, which will focus on startups and entrepreneurs.To learn more about Get Me Press and the services they offer visit www.getmepressnow.com.The company's mantra, according to a spokeswoman, is "We Tell Your Story Online." The team of experts collaborates closely with their clients, writing, editing, and publishing their story in prominent online journals and industry publications."We understand that entrepreneurs and company founders have ideas, and we have the infrastructure to help them turn those ideas into published contributions in prominent online journals.""We understand that entrepreneurs and company founders have ideas, and we have the infrastructure to help them turn those ideas into published contributions in leading online journals. This is why Get Me Press focuses on startups and founders," the spokesperson explained, adding that Get Me Press' writers have extensive expertise writing for major magazines and understand how to effectively communicate their clients' messages.According to the spokesperson, advice and profile pieces are one of the most successful ways to boost a Google Search ranking by driving hundreds of visitors to a website. Online content, on the other hand, tend to stay online longer than social media links, resulting in free organic traffic.Articles generate new SEO, which will aid in the development of a strong digital presence and a high search engine rank. These articles will generate free organic traffic while also providing backlinks and directing viewers to their clients' websites.According to the spokesperson, this publicity could provide a number of advantages, including the following:- Supercharged SEO - The entrepreneur's name on page one, two and three of the google-news search engine,- Increased brand visibility, credibility, and equity- Inbound traffic and leads to content and offers will improve.- Speaking engagements, capital investors, talent acquisition, and requests to be included in new online publications and podcasts are all exciting and unexpected prospects.Get Me PressAdrienne Greenwood and Michael Hall founded Get Me Press in 2022. They both have a diverse business expertise in strategic branding and communications, as well as creative digital marketing, and can advise their customers and brands on the best placements for their sector niche and budget. Please visit our website for additional information. Visit www.getmepressnow.com. Media ContactAdrienne Greenwoodinfo@getme.press Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Increases Carbon Neutrality Investments: Portfolio Company Talent New Energy Completes A++ Financing Round with Several Hundred Million RMB ACN Newswire

Legend Capital Increases Carbon Neutrality Investments: Portfolio Company Talent New Energy Completes A++ Financing Round with Several Hundred Million RMB

HONG KONG, Jun 16, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Capital's portfolio company Talent New Energy, a new Chinese powerhouse in the solid-state battery industry, recently announced the completion of its Series A++ financing round with several hundred million RMB. Legend Capital initially invested in Talent New Energy by joining the Pre-A financing round and continued to support the company's development by following up this Series A++ financing round.With the improved battery technology and continuous high oil prices, the penetration rate of new energy vehicles is rising. The penetration rate of new energy vehicles in China reached 25.3% in April, and according to the industry forecasts, it will increase to 35% by the end of the year. Under the global background of carbon peaking and carbon neutrality, the wind power, photovoltaic and energy storage industry are also ushering in a golden era, gradually replacing the traditional fossil energy. With the technical advantages of high safety and high specific energy, it is widely believed in the industry that solid-state batteries will become the next trillion-level super track and the ultimate solution for battery technology.Technology innovation is the core path to support the realization of carbon neutrality. With the acceleration of vehicle electrification, applications such as energy storage have opened up a new trillion-level market. Legend Capital actively explores suitable investment opportunities in more advanced lithium battery technologies. As a brand-new technology solution, new energy solid-state batteries have been deeply explored by many giants and startups in China and around the world. With nearly 20 years of international and domestic solid-state battery R&D technology accumulation, the Talent New Energy team has determined the oxide technology route and the gradual development path from mixed solid-liquid to all-solid-state lithium battery since the establishment of the company in 2018.Legend Capital stated: "under the leadership of the founder Dr. GAO Xiang, the Talent New Energy team has been conducting R&D with the goal of industrialization, not only achieving a comprehensive breakthrough in product performance but also making Talent New Energy the leading semi-solid-state battery company in the market in terms of mass production capability. After the completion of the first investment in Talent New Energy last year, Legend Capital has continued to support the company's development by investing in each subsequent round of Talent New Energy's financing, helping the company become a leader in the solid-state battery industry in various aspects such as capital and industrial resources." It is reported that Talent New Energy's first semi-solid-state power battery production line in Chongqing will be put into production in October this year. Talent New Energy said that after this round of financing, the company would accelerate the integration of technological resources to set up an advanced energy materials research institute and a new energy technology industrialization joint R&D center in Beijing. The company is accelerating the mass production and commercialization of semi-solid-state lithium batteries and striving to launch the all-solid-state lithium-ion battery at the end of this year, providing advanced and reliable energy solutions to the new energy vehicle industry and electrochemical energy storage industry and providing "energy blocks" for the construction of new infrastructure for high-efficiency cross-space-time energy storage in the future human society. Under the goals of carbon peaking and carbon neutrality, Legend Capital's investments focus on energy system decarbonization, vehicle electrification/intelligence and synthetic biology. Energy decarbonization includes photovoltaics, wind power, smart grids; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others.Legend Capital has long been optimistic about the electrification, intelligence, and automation of new energy vehicles. It has invested in numerous enterprises in automation equipment, lithium batteries and material in the past 10 years, many of which were went public successfully, such as Wuxi Lead Intelligent (300450.SZ), CNGR Advanced Material (300919.SZ), Putailai New Energy (603659.SH), Hymson Laser (688559.SH), Colibri Technologies (002957.SZ). Legend Capital is also one of the early investors of CATL (300750.SZ). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Breakthrough Cooperation of Legend Capital’s Cross-border Portfolio Companies: Innovent and Etana Jointly Announce the Approval of Bevagen by the BPOM ACN Newswire

Breakthrough Cooperation of Legend Capital’s Cross-border Portfolio Companies: Innovent and Etana Jointly Announce the Approval of Bevagen by the BPOM

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - On June 14, two of Legend Capital's portfolio companies, Innovent Biologics, Inc. ("Innovent") and PT Etana Biotechnologies Indonesia ("Etana"), jointly announced that the Indonesian Food and Drugs Authority (BPOM) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for five indications including metastatic colorectal cancer (mCRC), metastatic triple-negative breast cancer (mTNBC), advanced non-small cell lung cancer(NSCLC), ovarian cancer (OC), and cervical cancer(CC). Under the approval of the BPOM, Bevagen will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.Dr. Michael Yu, Founder, Chairman and CEO of Innovent, said, "We are pleased that under the strategic collaboration with Etana, the approval of Bevagen in Indonesia marked a meaningful step toward bringing Innovent's innovative portfolio into the global market, benefitting patients globally. Pairing Etana's commercial expertise in the local Indonesian market with Bevagen's clinical profile, high-quality production and relative affordability, we are confident that Bevagen will launch to the market quickly and benefit many cancer patients."Nathan Tirtana, President Director of Etana, said, "Etana appreciates the support of BPOM for approving Bevagen for cancer patients in Indonesia. With this product, we believe we can provide better access to high-quality and affordable biosimilar drug to meet the need of cancer patients in Indonesia. Our next step is to implement the technology transfer and local Bevagen production in Indonesia via collaboration with Innovent."Legend Capital has been looking for investment and partnership opportunities in the Southeast Asian market since 2019 and ultimately invested in Etana in 2020. By leveraging the advantages of the portfolio ecosystem, Legend Capital has played an active role in promoting the strategic cooperation between Innovent and Etana.Mr. Frank Hong, Managing Director of Legend Capital, said, "Congratulations to Innovent and Etana for the approval of the first biosimilar in Indonesia. This milestone achievement demonstrates the feasibility of expanding Chinese innovative drugs market access into the emerging markets. The emerging markets along the Belt and Road have significant demand for pharmaceutical products and unmet clinical needs, Chinese innovative therapeutics are particularly well suited to the needs of patients in developing countries given their quality and affordable prices. Legend Capital will continue to explore investment opportunities in the emerging markets and actively pioneer the path for Chinese high-end biologics' overseas expansion, facilitating the globalization of Chinese pharmaceutical companies."Mr. Fei Qi, Executive Director of Legend Capital, said, "The cross-border investment and industrial collaboration in the Southeast Asian market possess unique challenges: from policy regulation, folk culture to healthcare system complexity. Etana has set up a competitive barrier of 'Access + Manufacturing + Commercialization' in Southeast Asia, and Legend Capital complemented Etana's key 'Business Development' ability by leveraging its healthcare portfolio ecosystem. Legend Capital has provided a series of value-add services in terms of company strategy, business cooperation and subsequent financing to Etana since its investment. Etana has approached and discussed collaboration initiatives with more than 10 Chinese biopharmaceutical companies and plans to introduce more therapeutics that Indonesia currently lacks, such as cancer monoclonal antibodies, COVID vaccines, and antiviral infection drugs. Through the joint efforts of Etana and its partners, we believe that the company will be able to provide high-quality and affordable Chinese innovative drugs to Indonesia, Southeast Asia and even the Islamic world."Legend Capital has been firmly positioned to invest systematically in the field of innovative medicine. Adhering to the investment philosophy of "Global Vision, Chinese Insights", Legend Capital is looking for truly internationally competitive technologies and teams to solve the unmet clinical needs; many of its portfolio companies have been listed on A-share or H-share successfully, such as Kawin Technology (688687.SH), Innovent Biologics (01801.HK), Hbm (02142.HK), Recbio Technology (2179.HK). At the same time, we also made investments in segment-leading companies such as GluBio Pharmaceutical, Ribo Life Science, PegBio, Exegenesis Bio, Lynk Pharmaceuticals and Innostellar Biotherapeutics. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Amazfit to Launch Bip 3 Series of Smartwatches in Malaysia from 15 June ACN Newswire

Amazfit to Launch Bip 3 Series of Smartwatches in Malaysia from 15 June

KUALA LUMPUR, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Amazfit, a premium smart wearable hardware brand owned by Zepp Health Corporation, is going Big with Bip in the latest launch of smartwatches catered to the pursuit of an active and healthy lifestyle.The Bip 3 will be launched online on 15 June while the Bip 3 Pro is available for pre-orders until 25 June, when it is launched online. The Bip 3 is available for the first seven days after launch on the Shopee e-commerce platform, of which the first three days is exclusive to Amazfit's flagship online store on Shopee.Encased in a super-slim and light body, there is nothing small about the Bip 3 series of smartwatches because when you Think Big, you Think Bip as these smartwatches powered by the Zepp OS operating system and leveraging on big data optimises technology to provide a whole range of personalised sports, health and lifestyle experiences.Jacob Jin (Amazfit SEA Director) Amazfit said, "Smartwatches in the US$25 to US$75 price category continues to grow globally. The Bip series is one of the top selling smartwatches priced between US$39 and US$49 with advantages in ID, screen size and endurance. Bip is Big in all the ways that count with a super-large display screen that allows the wearer to see more and do more."The Bip 3 series come with 1.69" LCD screens, over 50 vibrant watch faces, up to two weeks battery life, 5-ATM water resistance, over 60 sports modes and health monitoring that includes blood-oxygen saturation measurement, heart rate, stress level and sleep monitoring and, Personal Activity Intelligence health assessment system. Exclusive to Bip 3 Pro is the 5 Satellite Positioning Systems.The Bip 3, which comes in black, blue or pink, is priced at RM199 while the Bip 3 Pro, which comes in black, cream or pink, is priced at RM249. For the first 100 customers who gets their hands on a Bip 3, they will receive an exclusive Amazfit Headband."Bip is Big in letting the wearer express themselves as they can accessorise by choosing from a range of eye-popping watch faces that can be downloaded from the Zepp OS App. Wearers can customise which widgets to show on the editable watch face options or even upload of their favourite photos to the watch face."To know more on the Bip 3 series of smartwatches, please go to www.amazfit.com/en or to Amazfit's e-commerce partner platform http://bit.ly/Amazfit-MY-SHOPEE.Amazfit: www.amazfit.com/en Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
兴业银行:助企纾困出实招 稳住经济基本盘 ACN Newswire

兴业银行:助企纾困出实招 稳住经济基本盘

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 今年以来,兴业银行坚持稳字当头、稳中求进,聚焦重点领域、薄弱环节,持续加大实体经济金融支持,通过拓宽融资渠道、开辟绿色审批通道、下调贷款利率、减费让利等方式综合施策,打通融资“阻梗塞”, 拓宽企业“融资路”,为稳住经济大盘贡献兴业力量。截至5月末,兴业银行以企业客户为主的对公贷款余额2.35万亿元,较年初新增1950多亿元。兴业银行杭州分行针对物流企业特点,陆续推出无还本续贷、纯信用贷款等一系列服务方案,保障物流企业的日常运营。兴业租赁支持5家唐山市物流公司采购125台新能源重卡,保障运输“生命线”皇宝(石狮)实业有限公司生产车间辽宁省农药有限公司在为春耕集中备货四川飞亚动力科技股份有限公司生产车间打通“阻梗塞” 为物流畅通“加油”货运物流关系百姓生活,关系国民经济的发展和产业链的循环。今年以来疫情呈现多点散发、反复多变的态势,部分货运物流企业的正常经营受到巨大冲击。杭州乾元物流有限公司是“饿了么”的配送加盟商,拥有日处理“饿了么”配送5万单的能力。随着4月份杭州疫情的持续升级,封闭区逐渐增加,但公司运力不减,“骑士”们始终穿梭在城市的大街小巷,满足千家万户的物资需求。疫情期间,企业资金需求大,且在兴业银行的贷款即将到期。得知这一情况后,兴业银行开通绿色通道,为企业办理260万元无本续贷的“连连贷”业务,解除了企业的后顾之忧。无锡睿航物流公司也是兴业银行“连连贷”的受益者,在150万续贷资金支持下,短时间内还贷资金和流动资金双重压力迎刃而解。据悉,疫情期间,兴业银行持续加大对货运物流循环畅通的金融支持力度,对承担疫情防控和应急运输任务较重的运输物流企业开辟“绿色通道”,优化信贷审批流程,提供灵活便捷金融服务,对于因疫情影响偿还贷款暂时困难的运输物流企业,给予贷款展期和续贷安排,帮助货运物流行业纾困解难,以金融之力为物流畅通“加油”,保障供应链产业链安全。“疫情反复让我们经营压力倍增,借助兴业银行数字供应链产品,我们成功获得300多万元的贷款额度,让我们面对疫情更加从容!”一家唯品会合作企业负责人表示。兴业银行持续完善数字供应链金融产品服务体系,与福州朴朴和广州唯品会等生鲜类及服装类电商平台合作,通过兴享供应链平台与电商供应链平台创新融合,“一户一策”为电商平台上游供应商提供量身定制的一站式供应链金融服务,有效解决了疫情期间民生保供平台上游供应商的临时性资金需求,持续提升融资便捷性和可得性。运输车辆是物流畅通的生力军,兴业银行发挥综合经营优势,与旗下兴业租赁公司协同联动,为物流企业采购新能源重卡提供租赁资金支持,保障运输“生命线”。唐山港地处环渤海经济带核心地区,承担着环渤海地区钢铁、煤炭、汽车等工业大宗商品的吞吐任务。疫情期间,唐山港区大宗商品运输需全力保障,当地多个物流公司提出增购新能源重卡需求,急需金融支持。兴业银行全资子公司兴业金融租赁利用自主开发的普惠金融科技系统,在不足十天时间内,以融资租赁形式支持5家唐山市物流公司采购125台新能源重卡,采购金额8200多万元,当月即投入到唐山港区运输保供队伍中。普惠支小支农 稳住经济“底盘” 温州和喜和贸易有限公司是一家从事花岗岩、玄武岩等碎石建材的传统贸易型小微企业。因2022年春季疫情在长三角区域突发,企业外输物流受到冲击,大量石材囤积港口无法及时运输至下游客户,企业回款时间不断被延后,面对即将到期的100万元贷款犯了难。兴业银行温州分行得知情况后,主动与企业负责人沟通了解情况,为企业延长贷款六个月,全力帮助企业渡过难关。小微企业背后是千千万万的家庭和就业,是稳经济的基本盘。兴业银行针对小微企业等受困市场主体,强调不得盲目限贷、抽贷、断贷,通过提供中长期贷款、降低利率、展期或续贷支持等方式,不断提升小微企业融资便利度和可得性。同时,积极探索数字化金融服务新模式,努力实现小微企业贷款“增量、扩面、降价、提质”,为保市场主体注入更多金融活水。“早上到公司了解情况,下午就放款了,效率真是高!”在收到兴业银行泉州分行发放的970万元制造业企业贴息贷款后,皇宝(石狮)实业有限公司负责人欣喜地说。皇宝实业是一家从事漂染的高新技术制造企业,受疫情影响,该公司销售货款回笼较慢,急需资金用于稳定生产经营。兴业银行泉州分行在开展支持复工复产专项走访中了解到企业的情况后,立即协助企业通过福建金服云平台开设的“制造业中小微企业融资支持专项”专区申请办理,并于当天顺利放款,大大节省了企业成本。作为平台建设运营方,兴业银行依托福建金服云平台,将大数据持续转化为生产力,广引金融活水,为中小微企业提供更加便捷、精准的金融服务,截至目前,已解决中小微企业融资需求突破1500亿元,解决了36000家企业和个体工商户43800多笔贷款资金的燃眉之急。同时该行还充分利用互联网和大数据技术,开发了具有“线上申请、线上审批、线上放款、随借随还”特点的“快易贷”“合同贷”“e票贷”等线上融资产品,为政府采购、供应链上下游、银税互动等不同场景下的小微企业提供全流程的线上融资服务。在服务小微企业的同时,兴业银行聚焦粮食安全,围绕春耕备耕、粮食流通收储加工等全产业链,制定差异化信贷支持措施,加大对涉农主体的支持力度,为农业生产送来普惠“及时雨”。截至4月末,兴业银行涉农贷款余额5172亿元,较年初增加509亿元,增速10.9%。5月份,河南省8500万亩小麦陆续成熟并进入收获期,一派丰收景象丰收在望。在新乡辉县,由于去年遭受水灾比较严重,小麦播种比往年播种要晚,但农户们比往年更加渴望丰收。兴业银行新乡分行迅速开辟绿色通道,3天内为辉县市金穗粮油有限责任公司完成1000万元“粮储贷”的放款,确保颗粒归仓,农民“粮出手”“钱到手”。在东北粮仓辽宁,严峻的疫情,给辽宁省农药有限公司集中备货工作造成不小的挑战,如不及时解决资金问题,将直接影响当地的春耕进度。借助绿色审批通道,兴业银行沈阳分行迅速向企业发放了5000万元贷款,极大缓解了企业的备货困扰和资金周转压力,有效保障疫情防控期间春耕农资产品数量足、价格稳,为守护东北大粮仓贡献金融力量。拓宽融资“高速路” 降低企业“负荷量”在帮助企业纾困过程中,兴业银行在对企业加大信贷支持的同时,还创新融资方法,“商行+投行”拓宽企业融资的高速路,并通过减费让利等举措,降低企业负荷,让企业轻装上阵。四川飞亚动力科技股份有限公司是一家汽车零部件制造商,是国家级“专精特新”小巨人企业。日前,为满足该企业日常经营周转资金需求,兴业银行应用“技术流”体系,给予该公司信用免担保授信额度1000万元,有效满足了公司的融资需求,支持该公司持续发展壮大。相对于传统以企业财务状况为依据的“资金流”评价体系,“技术流”评价体系涵盖8个一级指标、17个二级指标,着重考察企业科技创新能力,并根据指标分值,给予企业技术流评级,破除了科创企业的融资难题。截至5月末,兴业银行通过“技术流”评价体系累计向企业投放资金余额726亿元。青岛航大新材料技术有限公司凭借国际领先的自主知识产权实现产学研的有机融合,并于2017年正式投入汽车轻量化材料的生产,近两年来稳步推进环保生产转型,并阶段性停产转移生产基地,让这家初创期企业资金面雪上加霜。兴业银行青岛分行深入调研后,发现企业在企业供应链中具有核心竞争优势,市场前景广阔,为企业量身设计了以私募股权基金投资为依据的“投联贷”专属服务方案,于今年5月末完成全部1000万元放款,并提供优惠利率,极大缓解了企业融资难题。 让企业跑起来,拓宽融资“高速路”的同时,必须降低企业负荷量。兴业银行围绕企业减费让利出台一系列政策,持续加大减费让利力度,为市场主体纾困减负,帮助其渡过难关,恢复发展。4月份,兴业银行新发放普惠小微企业贷款加权平均利率较2020年12月下降47BP。为进一步加大减费让利力度,该行在贯彻落实人民银行等四部委发布的《关于降低小微企业和个体工商户支付手续费的通知》要求基础上,自主加大减费让利力度,自2022年4月30日起,将对公账户/收支控制费、账户信息查询费、组合签章管理费等8个收费细项调整为免费,还适当下调部分与客户日常基础结算相关的项目收费标准,主动降低企业负担。仅今年一季度,该行服务收费减免金额约19亿元。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More

市场首批科创票据花落兴业银行

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 6月14日,兴业银行主承销的市场首批用途类科创票据成功发行,为象屿集团募集资金10亿元,专项用于厦门天马显示科技有限公司建设第六代柔性主动矩阵有机发光二极体(AMOLED)项目生产线项目,该项目为国内最大的柔性AMOLEO单体工厂。此前,兴业银行已于6月初主承销落地市场首批2单主体类科创票据,为中交第二航务工程局有限公司、云南省建设投资控股集团有限公司合计募集资金15亿元,支持科技创新引领产业升级。“科创票据精准支持了科创领域企业融资需求,进一步拓宽了债券支持实体经济路径,为科创领域提供了低成本直达资金,有效助力资本市场服务国家创新驱动发展战略。”兴业银行投资银行部总经理林舒表示。据了解,5月20日,交易商协会整合高成长型企业债务融资工具、双创专项债务融资工具和创投企业债务融资工具三大科技创新主题融资产品工具箱,升级推出科创票据,支持科创企业发债用于生产经营,非科创企业发债用于科创领域的股权投资、基金出资、项目建设等,引导资金向科技创新领域集聚,助力加快建设科技强国。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More

力保市场主体 兴业银行零售普惠小微贷款余额超2200亿元

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - “今年的樱桃收购,我们心里特别有底气,兴业银行为我们在线发放了200万元信用贷款,帮了我们樱桃果农的大忙。”大连金普新区大莲泡村的樱桃大棚里,大连一家果业集团工作人员正在忙碌收购果农刚采摘的樱桃,正是这笔贷款,让该果业集团有充足资金在各村设立收购点,也让果农不再为樱桃的销路担忧。3月以来,受新一轮疫情影响,很多小微企业、个体工商户经营受困。兴业银行心系实体,风雨同舟,坚决贯彻党中央国务院决策部署要求,以自身零售信贷体制机制改革为契机,着力完善“敢贷、愿贷、能贷、会贷”长效机制,全面提升小微企业及个体工商户零售信贷的可得性、覆盖面与便利度。截至2022年4月末,兴业银行零售普惠型小微贷款余额超2200亿元,较年初增长11%,当年个人经营贷发放逾700亿元,为“保市场主体保就业保民生”输送源源不断的金融活水。健全机制 确保敢贷愿贷实现普惠金融可持续发展,离不开体制机制保障。今年以来,兴业银行启动实施包括零售条线等在内的体制改革,在总行层面成立一级部门零售信贷部,进一步深化零售信贷业务集约化经营,建立更加敏捷高效的零售信贷工厂,提升普惠金融服务水平。在制度层面,该行出台《兴业银行零售小微贷款业务尽职免责实施细则》,明确零售小微企业贷款业务尽职免责的认定标准、免责范围等,进一步激发基层服务小微企业的内生动力。同时全面加快数字化转型,持续推进“天网工程”建设,以“数据+模型+系统+场景”为切入点,打造开放共享、数据驱动、模型探索、敏捷运维的零售智能风控中台,目前一期工程已上线,实现了全集团自然人风险数据的整合、共享与分层,支持对零售信贷风险的全方位扫描,全面提高了贷前、贷中、贷后风险甄别和预警能力,为高质量开展零售信贷业务保驾护航。创新产品 夯实能贷基础兴业银行鼓励各分行结合当地特色产业开展个人经营贷业务,形成“一行一策、一户一策”的贷款解决方案,为不同行业、不同经营群体提供融资支持,力争做到“哪里有需求,哪里就主动对接服务”。快经贷、商车贷、产业园区贷、创业贷、光伏贷……截至2022年4月末,兴业银行共计落地逾200个“兴惠贷”特色服务专案,覆盖全国200多个城市,有效满足小微企业资金周转需求,为地方经济注入生机与活力。为满足客户对贷款时效性、便捷性的要求,兴业银行还自研创设了消费兴闪贷、经营兴闪贷等全线上化个贷产品,并推出了针对存量经营贷客户无还本续贷的产品“连连贷”,针对房贷客户先还利息、暂缓还本金的产品“随薪供”等特色产品,灵活满足客户差异化需求,精准匹配最合适的产品。科技赋能 提升会贷能力兴业银行不断强化科技赋能,加快推动零售信贷向“个性化、便利化、智能化”升级。部分业务可实现当天放款,有的信用类贷款可实现秒级审批放款。例如,该行推出的个贷数字化应用项目之一“兴通途”可以实现个贷从进件、审批到放款全线上操作,客户通过“个贷工作室”“二维码收件”等线上功能即可实现贷款在线申请,服务体验大大提升。与此同时,兴业银行“兴智汇”APP线上审批功能可实现审批人员在移动端处理业务,让常在外跑业务的客户经理也可不受地理限制,随时随地移动办公。“不管是我们自己处理业务,还是帮客户查询审批进度,都非常方便。”基层的客户经理们纷纷点赞。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
HYPEBEAST旗舰大楼即将登陆美国 ACN Newswire

HYPEBEAST旗舰大楼即将登陆美国

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 结合现代文化与生活时尚、以及编辑自主之商业及新闻的首选平台Hypebeast(股份代号:0150.HK),首栋位于美国的旗舰大楼将于本周正式登陆曼哈顿唐人区Division Street 41号。楼高7层、约25,000 平方呎的空间将展现Hypebeast 整个潮流生态系统,当中包括HBX纽约旗舰店、Hypebeans 咖啡店、活动创意空间及集团办公室总部。图片由Hypebeast提供全球最大的HBX旗舰店将于6月17日正式开幕,把独特的潮流文化生活由网上带到纽约社群的现实生活中。两层空间由HBX的动态视角出发,将不定期转换主题。在一楼,整个空间可以从一个「庭院」无缝地摇身一变成活动场地、展览或品牌期间限定店,并设有美国首间Hypebeans 咖啡店,以高质量的咖啡和本地采购的小食连系小区,创造共同的最潮休闲地。在二楼则可探索超过40个最炙手可热的全球知名及新锐潮流男女服饰与高质素的生活品牌。三楼更设有一个创意空间,让各式各样的文化活动和品牌期间限定店都可以进驻Hypebeast的基地。而其余空间将会作为Hypebeast在北美的办公室总部,足以容纳逾百名员工。媒体查询:纵横财经公关顾问有限公司李惠儿 电话: (852) 2864 4834 电邮: vicky.lee@sprg.com.hk陈嘉盈 电话: (852) 2864 4890 电邮: ivy.chan@sprg.com.hk公司网址: https://www.sprg.asia/关于 Hypebeast (股份代号:0150.HK)Hypebeast 是全球知名的文化及生活潮流信息平台,以编辑为主导的角度提供不同内容及推介最新的潮流商品。Hypebeast 成立于2005年,并于2016年正式成为上市公司。至今Hypebeast 在各大平台的总使用者人数已达4470万,并在北美、亚太地区以及欧洲等地拥有庞大的读者群。近年Hypebeast 积极发展更多元化的业务,当中包括Hypebeast以及多个信息平台、网上商店HBX.com, 及创意制作公司 Hypemaker。更多信息请参阅 www.hypebeast.ltd。关于HBXHBX自 2012 年创立,是一个拥有超过 250 个精选品牌的全球电子商贸零售平台,集合知名及新兴的男装、女装和生活方式品牌。HBX专注于为客户提供最新、且引领潮流的时装、配饰、鞋履、家居和生活用品,策划最新的全球性和令人兴奋的品类。HBX 电子商务平台向全球 70 多个市场发货,并在香港和纽约设有零售店。更多信息请参阅 www.hbx.com。关于HypebeansHypebeans 是Hypebeast 第一个饮食相关的品牌,提供优质咖啡和公共空间。Hypebeans的使命是于传统咖啡店以外提供一种优质的生活模式,透过不同创意的结合和合作带来全新的文化体验。Hypebeans 在香港、首尔和纽约均设有分店,更多信息请浏览:https://hypebeans.com/。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
Asia’s Payments, E-Commerce & Banking Leaders to Gather Live Online in June, to Chart the Future of Commerce in the Region ACN Newswire

Asia’s Payments, E-Commerce & Banking Leaders to Gather Live Online in June, to Chart the Future of Commerce in the Region

Singapore, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Seamless Asia (www.terrapinn.com/virtual/seamless-asia/index.stm) returns live online this 22-23 June, gathering over 1,700 attendees virtually to explore the latest innovations in Asia across the payments, e-commerce and banking sectors."With digital payments in Asia forecast to exceed US$350 billion by 2026, e-commerce spending in Southeast Asia expected to reach US$180 billion by 2025 and more than 40 million new users joining the internet economy every year, there's never been a more exciting time in commerce," says Paul Clark, Managing Director - Asia for Terrapinn. "Over the last two years, these sectors have been at the forefront of innovation - now it's time to make sure they are positioning themselves for a post- pandemic era and securing their future growth. Seamless Asia offers them exactly that."Seamless Asia will bring together over 100 expert speakers across six key content pillars: payments innovation, e-commerce strategy, online payments, e-commerce marketing, banking and financial inclusion. Attendees will enjoy free access to all sessions on the platform, and all sessions will be available for on-demand viewing for one month after the event, truly offering attendees a chance to fit the event around their own schedule. Speakers at the event include:- Bonnie Mak, Head of eCommerce, Samsung- Julian Foo, Head of Payments & Instore, ShopBack- Theodora Lai, Chief Strategy Officer, Burpple- Brad Jones, Chief Executive Officer, Wave Money- Vrutika Mody, Head of Global Partnerships, GoPay- Kannan Rajaratnam, Regional Director of Payments & Customer Operations, Zalora- Jessica Lam, Chief Strategy Officer, WeLab- Dmitry Bocharov, Chief Product Officer, BigPay- Sarita Singh, Regional Head & Managing Director, Southeast Asia, Stripe- Cecilia Chan, Head of Marketing Hong Kong, Carousell Group- Dennis Valdes, President, Cebuana Lhuillier Bank- Kristy Duncan, Founder & CEO, Women in Payments- Arvie de Vera, Co-Founder & Chief Executive Officer, UnionDigital- Loek Berendsen, Global Platform Strategy Leader, IKEA- Esel de Sagun-Madrid, Head of Data Science & Advanced Analytics, Metrobank- Karthick Chandrasekar, Head of Product & Commercial, Digital Payments Group, DBS Bank- Sonal Kapoor, Senior Director, Flipkart- Kell Jay Lim, Head of Grab Financial Group (FinTech), Grab- Jean Thomas, Chief Marketing Officer, Pomelo Fashion- Debbie Watkins, Chief Executive Officer & Co-Founder, LUCY More than 30 sponsors, exhibitors & partners are supporting this year's virtual edition of Seamless Asia, including Title Sponsor Stripe, returning for the third year, Customer Retention Sponsor CleverTap and Platinum Sponsors Limelight Networks & Zendesk. All sponsors & exhibitors will be hosting a virtual booth on the platform for attendees to find out more about their products and services. Attendees will get a chance to interact directly with their teams.Details of the two-days event are as follows:Seamless Asia 202222-23 June 2022 | Virtual Free-to-AttendAbout TerrapinnTerrapinn has been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together, discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business. Whether you're looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change. Terrapinn - spark something.Press attendance is complimentary. Enquiries should be directed to: Jia Le LimMarketing Manager Terrapinn Asia jiale.lim@terrapinn.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
万隆、雅各臣及健倍苗苗成立合资公司 拓展大中华区及亚洲专科药及品牌医疗保健市场 ACN Newswire

万隆、雅各臣及健倍苗苗成立合资公司 拓展大中华区及亚洲专科药及品牌医疗保健市场

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 万隆控股集团有限公司(「万隆」,连同其附属公司「万隆集团」; 股份代号:0030.HK),其控股股东为云南白药集团股份有限公司(证券代号000538.SHE)、雅各臣科研制药有限公司(「雅各臣」,连同其附属公司(不包括健倍苗苗集团)统称「雅各臣集团」;股份代号:2633.HK)及健倍苗苗(保健)有限公司(「健倍苗苗」,连同其附属公司统称「健倍苗苗集团」;股份代号:2161.HK)今天联合宣布成立万隆雅健药业有限公司(「合资公司」),以把握大中华区及亚太地区专科药及品牌医疗保健市场的增长机遇。后排:由左至右:万隆行政总裁汤明先生及雅各臣执行董事及健倍苗苗非执行董事严振亮先生见证签约仪式;前排:由左至右:万隆执行董事及副行政总裁刘周阳先生及雅各臣首席财务官余振球先生签署合资公司协议合资公司由万隆、雅各臣及健倍苗苗分别拥有60%、20%及20%权益,将主要从事获取专科药(包括罕见病用药)、非处方药、品牌医疗保健品(包括草药产品)及医疗器械的授权,以及于大中华区及亚洲地区之经选定市场销售及分销该等产品,并发掘战略性合适的并购机会。凭借三家公司各自的市场知识、能力及网络,合资公司旨在于上述地区的高增长专科药物、品牌医疗保健品及医疗器械市场建立稳固的据点并实现实质商机。 万隆行政总裁汤明先生表示:「大中华区及亚太地区的医药、医疗保健及医疗器械市场的前景秀丽,加上後疫情時代下個人醫療保健意識日漸提高,為合資公司提供了巨大的市場潛力。从数据上来看,内地医药和医疗保健市场未来数年的年均增长率超过9%,增长十分强劲。我们很高兴与雅各臣和健倍苗苗建立战略合作伙伴关系,以扩大我们的医疗保健贸易产品组合,并利用我们的协同优势抓住及实现市场机遇。」雅各臣執行董事嚴振亮先生表示:「我们很高兴与万隆强强连手。并期望通过合资公司加强我们在大中华区及亚洲市场的据点。这次合作与我们市场扩展之策略不谋而合,合资公司将促进及加强我们于该等地区之专科药、品牌医疗保健品和医疗器械市场的准入,并透过合资平台为合作伙伴缔造交叉销售协同效应。」关于万隆控股集团有限公司(股份代号:0030)万隆控股集团有限公司为一间国际化的医疗保健产品贸易公司,业务遍及大中华地区及主要亚洲市场(包括日本、韩国及东盟国家),作为美国、瑞士及其他欧盟企业的品牌产品认可总代理,万隆的产品组合拥有广泛的精选医疗保健产品。有关万隆的更多详情,请浏览集团网站:http://0030.com.hk关于雅各臣科研制药有限公司(股份代号:2633)雅各臣是本地领先的医药公司,拥有垂直整合的业务,包括基础药物及专科药物的研发、生产、分销、销售及物流。作为本地主要的非专利药供货商,集团在香港私营及公营领域,具有最广泛的销售及分销的市场覆盖,并积极向策略性选择的亚洲市场伸延扩展。集团于香港设有10间PIC/S GMP认证的非专利药生产设施,并在各种治疗药物类别中拥有广泛的产品组合与享有优越市场地位。同时,集团一直致力透过增加各种高增值产品,策略性地扩大其非专利药的产品组合。扎根香港,集团已于中国、澳门、台湾、新加坡及柬埔寨开设营运子公司,建立区域性商业平台,以把握亚太区及大中华地区的市场潜力。而自 2017 年 6月 1 日,集团获纳入 MSCI 香港微型股指数成份股。更多详情请浏览雅各臣科研制药有限公司网站:http://www.jacobsonpharma.com/有关健倍苗苗(保健)有限公司 (股份代号:2161)健倍苗苗是设于香港的品牌医疗保健品推广及分销公司,产品据点遍及大中华、东南亚及其他选定国家。集团拥有丰富的营销专业知识并具备深厚的制药背景,秉承产品功效和质量至上的优良传统,在行业内定位独特,致力于满足消费者的保健需要。作为本地领先的品牌医疗保健品运营商,集团拥有一广泛系列品牌医疗保健品,包括品牌药、品牌中药及健康护理产品,其中包括「保济丸」、「何济公止痛退热散」、「德国秀碧除疤膏」、「德国宝宝手指水」、「美德玛宝儿除疤膏」、「唐太宗活络油」、「飞鹰活络油」及「十灵丹」等家喻户晓的传统品牌。有关集团详情,请浏览: www.jbmhealthcare.com.hk Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia ACN Newswire

Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Ban Loong Holdings Limited ("Ban Loong", together with its subsidiaries, "Ban Loong Group"; stock code: 0030.HK), of which Yunnan Baiyao Group Co., Ltd. (stock code: 000538.SHE) is the controlling shareholder, Jacobson Pharma Corporation Limited ("Jacobson", together with its subsidiaries (excluding JBM Group), "Jacobson Group"; stock code: 2633.HK) and JBM (Healthcare) Limited ("JBM", together with its subsidiaries, "JBM Group"; stock code: 2161.HK) jointly announced today on forming Ban Loong Jacobson JBM Pharma Limited (the "Joint Venture") to capture the growth opportunities of the specialty pharmaceuticals and branded healthcare markets in Greater China and the Asia-Pacific region.Back row: From left to right: Mr. Tang Ming, Chief Executive Officer of Ban Loong and Mr. Yim Chun Leung, Executive Director of Jacobson & Non-executive Director of JBM witness the signing ceremony; Front row: From left to right: Mr. Liu Zhouyang, Executive Director & Deputy Chief Executive Officer of Ban Loong and Mr. Yu Chun Kau, Chief Financial Officer of Jacobson sign the Joint Venture AgreementThe Joint Venture, which is owned 60% by Ban Loong, 20% by Jacobson and 20% by JBM respectively, will principally engage in the in-licensing of specialty pharmaceuticals (including orphan drugs), over-the-counter medicines, branded healthcare products (including herb-based products) and medical devices, and the sales and distribution of the products to Greater China and selected markets in Asia, alongside tapping merger and acquisition opportunities with a strategic fit. Leveraging the partner companies' respective market knowhow, capabilities and network, the Joint Venture is aimed at establishing a strong foothold and realizing tangible business opportunities available in the high-growth specialty pharmaceuticals, branded healthcare products and medical device markets in the aforementioned regions.Mr. Tang Ming, Chief Executive Officer of Ban Loong, said, "In light of the promising growth of the pharmaceutical, healthcare and medical device markets in Greater China and the Asia-Pacific region, coupled with the increased awareness of personal healthcare in the post-pandemic era, there is a substantial market potential for the Joint Venture to capture. Indeed, a strong growth forecast is also expected in the next few years, with an average annual growth rate of over 9% in the pharmaceutical and healthcare markets in China. We are excited with the strategic partnership with Jacobson and JBM in expanding our healthcare trading portfolio and riding on our synergetic strengths to seize and realize the opportunities in the markets."Mr. Raymond Yim, Executive Director of Jacobson, said, "We are very honored to partner with Ban Loong and aspire to strengthen our foothold through the Joint Venture in Greater China and markets in Asia. In line with our market expansion strategy, the Joint Venture will facilitate and enhance our access to the specialty drugs, branded healthcare products and medical devices markets in the regions, as well as generate cross-selling synergies for respective partner's products marketed and distributed through the Joint Venture platform. "About Ban Loong Holdings Limited (Stock Code: 0030)Ban Loong Holdings Limited is an internationalized healthcare products trading company with its business presence covering Greater China and key Asian markets including Japan, South Korea and ASEAN countries, as an authorized general agent for branded products from the United States, Switzerland and other European Union firms, Ban Loong possesses a wide range of well-selected healthcare products in its portfolio. For more details about Ban Loong, please visit the Group's website: http://0030.com.hkAbout Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high-value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.comAbout JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritizes product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines and health and wellness products, which include well-recognized household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan and Shiling Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
10 winning start-ups stand out at Start-up Express ACN Newswire

10 winning start-ups stand out at Start-up Express

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - The fifth edition of Start-up Express, an entrepreneurship development programme organised by the Hong Kong Trade Development Council (HKTDC), came to a successful conclusion today. The Pitching Final, which was streamed live, saw 10 winning start-ups selected from a total of 20 shortlisted companies. The "My Favourite Start-up Award", decided through live online polling, was awarded to Good Food Technologies, while the newly added ESG Award went to i2Cool in recognition of its sustainable and socially efficient business solution. The 10 winning teams will participate in a series of local and international events to develop their businesses by building connections, exploring markets, seeking partners and enhancing brand awareness.The Start-up Express Pitching Final winners pictured together with the judging panel and special guests. Ben Cheng, Managing Partner, C Ventures; Jason Chiu, Chairman, Hong Kong Start-up Council; Stephen Liang, Assistant Executive Director, HKTDC; Raymond Yung, Vice Chairman, AMTD Group; and Arshad Chowdhury, Managing Partner, Betatron Venture Group [back row, L-R]The distinguished judging panel witnessed the rise of the latest cohort of Start-up Express winnersRenowned stand-up comedian Vivek Mahbubani was the event's host, taking the opportunity to chat with entrepreneurs from some of the participating start-upsStephen Liang, HKTDC Assistant Executive Director, said: "As the pandemic situation gradually begins to ease, innovative business models and ideas will become a new stimulus for the economy in post-pandemic times. The enrolment for Start-up Express 2022 reflected the great enthusiasm of Hong Kong's entrepreneurs, with 20 shortlisted start-ups coming from a broader spectrum of fields than ever before, including arts tech, green tech, health tech, prop tech, fintech, smart city tech, edtech, food tech and others. Over the past four years, the programme has nurtured 40 start-ups and the HKTDC continues to pass on the spirit of entrepreneurship in Hong Kong, assisting local start-ups in growing their businesses to the next level. At the same time, we strive to create a sustainable and international entrepreneurial ecosystem."Diverse opportunities offered to winning start-upsPitching Final contestants presented their innovative business ideas and responded to questions raised by a distinguished panel of judges as well as the online audience. This year's judging panel comprised Raymond Yung, Vice Chairman, AMTD Group; Jason Chiu, Chairman, Hong Kong Start-up Council; Andrew Young, Associate Director (Innovation), Sino Group; Ben Cheng, Managing Partner, C Ventures; and Arshad Chowdhury, Managing Partner, Betatron Venture Group. The 10 winning start-ups are: Allklear Health, Beth Bioinformatics, Calioo Technologies, Custonomy Company, EggLogics, Flow, Good Food Technologies, i2Cool, MixCare Health and PONS.ai (click here https://tinyurl.com/2p8kvfxs to download the list of winners and their company profiles). The HKTDC will arrange a series of exposure opportunities through which the winning teams can interact with buyers and investors.Outstanding presentations at Pitching FinalAMTD Group was the exclusive Strategic Partner of Start-up Express for the fourth consecutive year. Calvin Choi, Chairman and Chief Executive Officer of AMTD Group and Founder of AMTD IDEA, shared his thoughts on the contest, saying that all the contestants presented extraordinary business ideas. "This is the fourth year that AMTD has supported HKTDC's Start-up Express as an exclusive Strategic Partner. The wide range of start-ups participating in this year's Pitching Final continue to innovate and develop in a more diverse and contemporary way. In particular, we saw more start-ups coming from art tech, food tech and other emerging areas this year, which shows that local start-ups are market-sensitive, quick to respond to the direction and dynamics of emerging industries, as well as reactive to rising trends and fads of the times," Mr Choi said.Noting that local businesses across different sectors had been affected by the pandemic, he added: "It is encouraging to see Hong Kong start-ups remaining active despite the difficulties and on the lookout for opportunities under the new normal. Government policies and the social environment have been very supportive of start-ups, too. I am confident that if local start-ups can continue their efforts, stay flexible and be determined to find unique opportunities in the new normal, they can definitely stand out from their competitors in an ever-changing business environment and find a sustainable way forward."The "SpiderNet Start-up Award", established to recognise the top performer selected by AMTD in the Pitching Final, was awarded to EggLogics. The award aims to provide the winner with an exclusive opportunity to access the resources and network of the AMTD SpiderNet ecosystem. The winner will benefit greatly in terms of its future business development and at the same time create synergies with other entrepreneurs within the ecosystem.Jason Chiu, Chairman of the Hong Kong Start-up Council and a member of this year's judging panel, said: "It is my pleasure to be on the judging panel again this year. There is tremendous competition in this year's contest. All the start-up teams used their innovative mindsets to deliver exceptional pitches and shone through, highlighting the fact that local tech talents are extremely capable. I am confident that Start-up Express will serve as a springboard for the winning teams to access more opportunities. They can leverage this platform to expand their business network, explore markets in Mainland China especially the Greater Bay Area and overseas, and take their business to the next level."Start-up Express boosts brand awareness and network expansionStart-up Express provides start-ups with the chance to promote their business ideas and enhance their brand awareness while connecting with investors and industry leaders, as well as acquiring business know-how from industry experts. Calvin Cheng, founder and CEO of Wizpresso which was a winner in the 2021 Start-up Express, said: "With the assistance provided by the HKTDC, we gained a lot of exposure that helped greatly with our brand promotion. We also had the chance to participate in international trade fairs to connect with potential clients. These are the kind of valuable opportunities open to Start-up Express winners."Logistics platform Zeek, another winning team at last year's Pitching Final, has successfully established a presence in Vietnam, Thailand, Singapore, Malaysia and other markets. KK Chiu, CEO of Zeek, said the company was able to grow its business connections by meeting with different businesses under the coordination of the HKTDC. Through HKTDC-organised local and overseas events, it also gained the opportunity to promote its brand to other local and international businesses.Start-up Express International Edition launches in DecemberThe HKTDC has always given its full support to Hong Kong's entrepreneurial ecosystem, helping to maintain the city's status as a competitive business centre and hub for innovation. In celebration of the fifth anniversary of Start-up Express, the first International Edition of the contest will be held this December as part of HKTDC Entrepreneur Day. Winning teams from Hong Kong will compete with outstanding start-ups from Mainland China, USA, the UK, Germany, Israel, Japan, Korea, Singapore and other countries and regions. Winners in the International Edition will be offered comprehensive assistance to enter the Hong Kong market and explore opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area via the Hong Kong platform.Start-up Express website: https://portal.hktdc.com/startupexpress/en/Photo download: https://bit.ly/3HnvEBWAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia enquiriesPlease contact HKTDC's Communications & Public Affairs Department:Clayton Lauw, Tel: +852 2584 4472, Email: clayton.y.lauw@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech 的亚太地区和美国领导团队参加 BIO 2022 ACN Newswire

Novotech 的亚太地区和美国领导团队参加 BIO 2022

SAN DIEGO, CA, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - Novotech 是亚太地区领先的生物技术临床研究机构,最近将其服务扩展到美国,将邀请来自亚太地区和美国的主要高管参加 BIO 2022,与所在亚太地区的生物技术公司会面,以加快他们的临床试验进程。 #4907在 此处 与 BIO 的一位 Novotech 专家预约会面 https://novotech-cro.com/contactNovotech 在亚太地区以提供全方位服务、高质量的快速临床试验而享有盛誉,现在可以在美国为其生物技术客户提供临床服务,以支持后期的全球研究。Novotech 现在在澳大利亚、韩国、大中华区、东南亚、印度、南非和美国拥有约 2,500 名临床试验专业人员。Novotech 首席执行官 John Moller 博士表示,Novotech 的亚太和美国团队利用世界一流的数据和最先进的技术(包括能够加速跨地区临床试验的解决方案)支持具有成本效益的快速临床研究。“过去五年对亚太地区生物技术临床研究的关注使该地区成为增长最快的临床试验目的地,中国成为新试验的主要地点,其次是美国。亚太地区为加快临床试验提供了令人信服的解决方案,尤其是在肿瘤学领域,因为其庞大的患者群体、竞争较少的临床试验环境和世界级的 KOL,此外,中国等监管改革加快了审批流程。向美国进驻是一项战略举措,旨在为我们希望在亚太地区和美国进行试验的美国客户以及希望在美国进行临床项目的亚太地区客户提供基于美国的专业知识和基础设施。” “客户将获得无缝服务,采用统一的系统和 SOP 方法,” Moller 说。根据全球数据白皮书: 与美国和欧盟相比,亚太地区临床试验的演变5* 在过去五年中,在亚太地区、美国和欧盟5 注册了超过 70,000 项新的临床试验。亚太地区是最大的贡献者,超过 50% 的试验其次是美国(29%)和欧盟五国(17%)。亚太地区已成为开展临床试验的首选目的地,因为其患者人数众多、易于遵守法规、开展研究的成本低、高质量标准和顶级临床站点的存在。* https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5关于Novotech健康控股Novotech健康控股有限公司(“Novotech”)是亚太地区及美国领先的生物技术专家 CRO。 Novotech 是一家 CRO,拥有综合实验室和 I 期设施,提供药物开发咨询和临床开发服务。它有助于在所有试验阶段和广泛的治疗领域成功进行大约 3,700 项临床试验。Novotech具有明显优势,可以为在亚洲及美国进行临床试验的生物制药客户提供服务。详细信息请访问 https://novotech-cro.com/contact媒体联系人David JamesE: communications@novotech-cro.com澳大利亚: +61 2 8218 2144美国: +1 415 951 3228亚洲: +65 3159 3427 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
Lifewire and The Harbour School Join Hands for the “e.a.r.t.h. Project” ACN Newswire

Lifewire and The Harbour School Join Hands for the “e.a.r.t.h. Project”

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Lifewire and The Harbour School join hands to honour Hong Kong's cultural history with the 'e.a.r.t.h. Project', breathing new life to the century-old Tai Tam Tuk Raw Water Pumping Station Staff Quarters Compound monuments. The site will be re-imagined as an early years campus for The Harbour School (THS), a K to Grade 12 international school well known for its world-class marine science program and inclusive ethos. Named the Earth Campus, it will provide approximately 150 places for children aged 3-8 (from PN - K3 initially). With its proximity to the Tai Tam Waterworks Heritage Trail featuring Hong Kong's rich waterworks, architectural and engineering history, the Earth Campus will also serve as an open space for education, leisure and cultural activities for the public, including guided tours, nature-related activities, wellbeing programmes, arts and music events. A Water Gallery displaying the history of the water supply in Hong Kong and the historical significance of the monuments, a new Annex with a viewing platform at the roof to allow the public to appreciate the front facade of the Pumping Station, the waterfront and nearby environment and social activity cum display areas will be set up for the public. As a highlight of Batch VI of Revitalisation Scheme from the HKSAR Government, the e.a.r.t.h. project is expected to be completed in 2028. The campus design will take into account the principle of "minimum intervention" and "reversibility" to preserve all characters defining elements of the monuments. Guided tours will be provided to educate the public about the architectural history of the Tai Tam Tuk area, as well as the revitalisation process of the monuments and their surrounding areas. Efforts will be made to collaborate with the community and like-minded NGOs to provide job opportunities for those in underprivileged families, including at-risk youths. Lifewire is a registered charitable institution with a vision to empower those in need in society and child patients with rare diseases and their families through supporting education and its future development. Its partner, THS, is an international school with forward-looking values and provides differentiated instruction for mainstream and neuro-diverse students. It is internationally recognised for its high-quality, award-winning experiential learning programs, and was named Best International School in Hong Kong Living's Education Awards 2021 for its outstanding social studies curriculum and technology program. At the International School Awards 2022, THS won for its marine science program and was also a Merit Winner in the Green Council's first Sustainable Development Goals (SDG) Achievement Awards. Ms. Rita Pang, Director of Lifewire Foundation Limited and Founder of See Change Education, said: "We feel very grateful to have this opportunity to reimagine the e.a.r.t.h. Project together with support from the government and the community including the Tai Tam Tuk Village Residents Fraternity Association, Tai Tam Tuk Dragon Boat Association, Scout Association of Hong Kong, etc. We are excited to work with education visionaries at the THS to set the platinum standard for inclusive schools in the future. Earth Campus will not only provide students with a unique environment for experiential learning that is rare in Hong Kong, but also serves as a scenic hub for the community to develop an appreciation for culture, history and heritage conservation."Dr. Jadis Blurton, Head of School of THS, said: "We are honoured and grateful to be working with Lifewire, the government and the community on this project of immense importance to Hong Kong's cultural history. The Earth Campus's waterside location provides an ideal setting for our award-winning marine science and social studies programs which are experiential, interdisciplinary, active and hands-on. THS welcomes diversity in our student body and has been delivering innovative approaches to learning since 2007 that benefit a wide range of learner abilities and put the joy back into learning and school. We are also excited by the opportunity to design activities to share with and educate interested members of the public about this site's fascinating architecture, ecology, and heritage."Ms. Carolyn Campbell, Parent of THS, said "The Harbour School's inclusive ethos and individualised education meant that all three of my children are able to go to the same school, including my child with additional learning needs who otherwise would not be able to access the local state curriculum. The Earth campus will enable access to high-quality education for all types of learners." 'e.a.r.t.h.' represents 'eco', 'art & culture', 'revitalisation', 'technology' and 'heritage', and it broadly captures the goals of the project to revitalise the Tai Tam Tuk Raw Water Pumping Station Staff Quarters Compound site using green construction with an emphasis on preserving heritage, conserving ecology, and promoting art, science and culture. The site includes extensive grounds which will provide nature-based and outdoor educational opportunities for its students. Alongside the school campus, we will establish a Water Gallery to promote the Tanka Boat Culture and the history of Hong Kong's waterworks. Bringing together the beauty of nature and education, our plan shall include guided eco-tours, mangrove planting, nature walks, wellness events, and other family-friendly leisure activities to encourage public participation and appreciation of the area and the Tai Tam Waterworks Heritage Trail. About LifewireLifewire (www.lifewire.hk) is a registered charitable institution founded in 2014. It is committed to bringing together corporates, chambers of commerce, organisations, and volunteer teams from all walks of life to help rare disease child patients and their families with medical and daily expenses, providing support and counseling, and spreading awareness about rare diseases to the society. Since its establishment, Lifewire has raised over HK$18 million for over 600 families. Its mission also encompasses life education, as Lifewire regularly visits campus to share the life stories of children who suffer from rare diseases, hoping to empower and encourage those children with rare diseases and inspire students to learn from them. About The Harbour SchoolThe Harbour School (THS) is a K to Grade 12 international school that aims to unlock the best in every student by taking a highly individual approach to teaching. The school was founded in 2007 and is already gaining a worldwide reputation as a center of excellence. It applies international best practices in adapting the US curriculum with an emphasis on 21st-century skills such as problem-solving, communication, teamwork, creativity and innovation. THS was named Best International School in Hong Kong Living's Education Awards 2021 where it also won awards for outstanding social studies curriculum and technology program. At the International School Awards 2022, THS won for its marine science program and was also a Merit Winner in the Green Council's first Sustainable Development Goals (SDG) Achievement Awards. For more information, please visit: www.ths.edu.hkMedia Inquiries:Yuki Lee (852) 3758 8355 yuki.lee@asiaalliedgroup.comSophie Po (852) 3758 8337 sophie.po@asiaalliedgroup.comNatalie Shiu (852) 3758 8366 natalie.shiu@asiaalliedgroup.comMaria Copp (852) 3905 0180 mariacopp@ths.edu.hkTo download all high-resolution images, please visit:https://www.dropbox.com/sh/wotmhbwi06s80oy/AABjE4mDJirLknt_Rrar_cCAa?dl=0 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
中国抗体在美国完成SM17 I期临床试验首例健康受试者给药 ACN Newswire

中国抗体在美国完成SM17 I期临床试验首例健康受试者给药

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 中国抗体制药有限公司(“中国抗体”或“公司”,连同其附属公司,统称“集团”;股份代号:3681.HK),专注研究、开发、制造及商业化免疫性疾病疗法的香港生物制药公司,欣然宣布,其一类新药(First-in-Class)SM17(注射用人源化抗IL-17RB单克隆抗体)在美国完成其I期临床试验之首例健康受试者给药,目前受试者情况正常。SM17是一款全球首创针对IL-17RB靶点的人源化IgG4-κ单克隆抗体。SM17最初由LifeArc(英国领先的医药研究慈善组织)与Andrew McKenzie博士共同开发并委托授权给中国抗体进行后续的临床研究与商业化。Andrew McKenzie博士(英国皇家学会会员)也是我们中国抗体科学顾问委员会成员。SM17结合IL-17RB受体后,可抑制人白细胞介素25(IL-25,一类关键的“警戒素”)导致的Th2细胞相关免疫反应,而IL-25已被证明与气道细胞的病毒感染以及过敏性疾病如哮喘的病理变化有关。患有未受控制的严重哮喘疾病患者,会承受哮喘反复发作及住院的风险;未受控制的严重哮喘疾病也会引起死亡率及患病率的升高、生活质素的下降以及医疗支出的增加等一系列问题。公司相信靶向Th2细胞相关炎性上游细胞因子通路(例如IL-17RB)的疗法,将能够在较前端从相关免疫级联反应控制哮喘等气道炎性相关疾病的发生及进展。公司相信SM17有潜力满足现有哮喘治疗中未满足的医疗需求。FIH的I期临床试验主要是在健康受试者中进行单次递增剂量(SAD)研究和多次递增剂量(MAD)研究,目的在于研究SM17在健康受试者中的安全性、耐受性、药效及相关药物代谢反应。SM17新药研究申请(IND)于2022年3月11日获得美国食品药品监督管理局(FDA)批准。尽管疫情爆发,中国抗体依旧快速在美国启动I期临床试验之首例健康受试者给药计划。此次I期临床试验的启动是中国抗体与LifeArc合作的重要里程碑,也从侧面验证了中国抗体在新药研发方面的的高效执行力。LifeArc首席执行官Melanie Lee提到:“LMB在抗体研发领域已深耕多年,LifeArc与Andrew McKenzie博士共同合作开发了SM17。Andrew McKenzies博士研究开发靶向IL-17RB的临床候选药物,然后利用LifeArc的人源化技术将靶向IL-17RB的抗体候选药物人源化,最终得到我们的人源化抗IL-17RB单抗。之后,LifeArc授权中国抗体进一步进行SM17的临床研究与后续商业化开发。我们很高兴SM17已经在美国启动I期临床试验,并完成首例健康受试者给药,希望SM17的顺利开发能够为现有疗法无法改善病情的严重不受控制的疾病患者带来福音。”中国抗体主席、执行董事兼首席执行官梁瑞安博士表示:“SM17已在I期临床试验中顺利完成首例健康受试者给药,SM17 I期临床试验的顺利启动是整个管线研究开发过程的一个重要里程碑。继旗舰产品SM03临床III期病人入组完成,预计2023年申请新药上市,核心产品SN1011适应症范围不断扩大,不同适应症的新药研究申请不断获得监管机构获批并计划在今年开展多项适应症的II期临床试验后,我们的SM17又顺利的进入I期临床,并完成首例健康受试者给药。公司产品管线的不断丰富进一步证明公司同时推进多项研发项目的能力。我们对SM17的临床开发以及商业化机会充满信心,我们将继续加快推进项目,坚持独立创新的理念,为患者谋求福祉、为股东创造价值。”关于LifeArcLifeArc是一家以自筹资金为主,英国领先的医药研究慈善组织。它通过与学术界、工业界、慈善机构和患者团体等展开合作,发掘早期新药项目,帮助新药的研究以满足广大患者未被满足的医疗需求。它在伦敦设有办事处,在斯蒂夫尼奇和爱丁堡设有科研机构,以及一支在伦敦弗朗西斯·克里克研究所工作的专业科学团队。关于中国抗体制药有限公司中国抗体制药有限公司专注于研究、开发、制造及商业化免疫性疾病疗法。公司注重创新研发,其旗舰产品SM03为全球首项用以治疗类风湿关节炎的潜在抗CD22单抗,已在中国进入类风湿关节炎三期临床试验,并被列为国家十三五重大新药创制专项重大项目。此外还有多个同类靶点首创(First-in-target)及同类首创(First-in-class)在研药物,部分已处于临床阶段,适应症范围覆盖类风湿性关节炎、系统性红斑狼疮、寻常型天疱疮、非霍奇金氏淋巴瘤、哮喘等具有重大未满足临床需求的疾病。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. ACN Newswire

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject has been dosed in the Phase I clinical trial of SM17 in the U.S. SM17 is a First-in-Class (FIC) humanized anti-IL-17RB monoclonal antibody. The subject is currently in a normal condition.SM17 is the world's first humanized IgG4-k monoclonal antibody targeting IL-17RB. SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom). SM17 was originally developed by Dr. Andrew McKenzie, FRS, who also serves as a member of the Company's Scientific Advisory Board, at the MRC Laboratory of Molecular Biology (LMB).SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of airway viral responses and allergic diseases, such as uncontrolled severe asthma. Uncontrolled severe asthma is associated with increased mortality/ morbidity, diminished quality of life and increased health expenditures. These patients are at a risk of recurrent asthma exacerbations and hospitalizations. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB on ILC2s, will have a broad effect on airway inflammation. The Company believes the huge potential of SM17 could satisfy unmet medical needs in asthma treatment. The Phase I study is a Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) to investigate the safety, tolerability and pharmacokinetics of SM17 in healthy subjects.SM17 received Investigational New Drug (IND) approval from U.S. Food and Drug Administration (FDA) on 11 March 2022. Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial. This marks a significant milestone on the collaboration between SinoMab and LifeArc, and demonstrates the efficient implementation of SinoMab's new drug R&D programs.Melanie Lee, Chief Executive Officer of LifeArc, said: "We applied our antibody capabilities when working with Dr. Andrew McKenzie at the LMB, to firstly generate and select a clinical candidate antibody targeting IL-17RB, and then humanise it. After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients. It's so rewarding to know that this antibody is going into trials and could eventually make a difference to people with severe asthma."Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "SM17's successful first-in-human dosing in Phase I clinical trial marked another milestone in our pipeline development. Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage. This further assures our potential commercialization prospects and proves our capability for progressing multiple assets of R&D concurrently. We are confident of the enormous prospects for SM17's clinical development as well as our commercialization opportunities in general. Moving forward, we will accelerate implementation of our projects, adhere to our vision of independent innovation to bring benefits to patients and create value for shareholders."About LifeArcLifeArc is a self-financing and leading UK medical research charity. It partners and works with academics, industry, charities and patient groups to unlock the potential of early stage science. It has an office in London and scientific research facilities in Stevenage and Edinburgh. It also has a specialist science team working at the Francis Crick Institute in London.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Sarawak Consolidated Industries Berhad Welcomes New Batch of Trainees for Industrial Training ACN Newswire

Sarawak Consolidated Industries Berhad Welcomes New Batch of Trainees for Industrial Training

KUCHING, MALAYSIA, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - Sarawak Consolidated Industries Berhad (SCIB), a civil engineering specialist, is pleased to welcome a new batch of trainees from Institut Latihan Perindustrian Kota Samarahan (ILPKS), Sarawak, to the Company for physical training as part of the industrial training programme in their final year.Rosland bin Othman, Managing Director and Chief Executive Officer of SCIBILPKS was established by the Department of Manpower under the Ministry of Human Resources in 1999, to meet the needs of Malaysia's skilled workforce by providing vocational training at the intermediate level with specialisation in high-tech fields and in-line with the need for technological developments in the manufacturing sector.The trainees were accepted into the programme following a Memorandum of Understanding (MoU) signed between the SCIB and ILP Kota Samarahan in October 2020. The MoU gives opportunities for industrial students to undergo training; offers industrial instructors places for industrial attachment training; offer job opportunities to qualified Institut Latihan Jabatan Tenaga Manusia graduates and offers short-term courses to SCIB employees who want to upgrade their skills.At the ILPKS Convocation Ceremony today, Managing Director and Chief Executive Officer of SCIB, Encik Rosland bin Othman, said, "Professional management on human capital is what we strive to do in SCIB. The younger generations are the future of any institution and even the country and that is why we must focus on the youth as they are the foundation of our society.""We provide them with a platform to learn and grow, thus giving them better understanding of their craft and the industry. Employment shall be given to promising students as well. We also believe that providing opportunity for our employees to expand their knowledge, expertise and experience with the course."Over the years, SCIB has trained approximately 179 trainees with specific skillsets such as engineering, accounting, business management and construction, while pursuing their certification, diploma and degree. These skillsets allowed the trainees to be employed in their chosen careers. Several trainees had the opportunity to be a part of the SCIB family.Sarawak Consolidated Industries Bhd: 9237 [BURSA: SCIB], scib@scib.com.my, http://scib.com.my Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
iRad于今年内开设三间全新医学扫描诊断中心 ACN Newswire

iRad于今年内开设三间全新医学扫描诊断中心

HONG KONG, Jun 14, 2022 - (亚太商讯 via SEAPRWire.com) - 黑桃资本有限公司(「黑桃资本」)旗下的医疗健康业务卓智医疗控股有限公司(「iRad」)刚宣布,为针对香港市场对影像诊断服务持续上升的需求,其于2022年的首半年已开设多三间医学扫描诊断中心,为客户提供全面的医学扫描诊断服务,包括磁力共振(MRI)、计算机扫描(CT Scan)、2D和3D乳房造影、超声波和X光等。同时iRad继续与多间国际知名保险公司、政府机构、著名私家医生、本地医疗集团、跨国企业、香港上市公司及非牟利机构展开合作,藉此扩阔强大的客户网络。iRad市场总监Crystal Yeung女士及iRad行政总裁Kin Wong先生继今年第一季开幕的旺角雅兰中心13楼后,iRad在6月上旬于中环核心商业地段再度扩张,选址中环皇后大道中139号 The L. Place 12及13楼全层,毗邻多幢甲级商业大厦,距离中环中心(The Center)的士站更是少于30秒的步行路程。顾客可于The L. Place门前上落车,方便一众行动不便的人士。此中心更增添共三部新型号MRI及CT扫描仪器,确保为顾客提供更高影像质素。iRad行政总裁Kin Wong先生表示:「iRad为独立医疗机构,我们并不隶属任何医疗集团。作为香港最具规模的私营专业医学扫描诊断中心,iRad成立至今近17年,我们与时并进,不断加装更多高端仪器和吸纳不同专业医疗人才,一直致力为每位病人及合作伙伴提供最佳的医疗体验。由于人口老化等问题对医疗系统带来压力,加上社会健康意识提高,更多人希望透过全身磁力共振(Whole Body MRI)来进行检查,及早发现身体异常的情况。现时,iRad合共拥有7间扫描诊断中心,其医疗团队更拥有约120名员工,包括放射科医生、放射科技师、护士和支持人员,服务近80万位病人。在医疗数据全数码化的趋势下,我们今年亦会对现有的基建系统进行技术升级,使医生能够更快捷地收到病人影像,满足电子化实时存盘需求,大大缩短报告时间,令整个过程更具效率。」有关黑桃资本有限公司黑桃资本有限公司乃何猷龙先生的家族办公室,负责管理何先生的私人资产发及财富项目。总部设于香港,公司的全球投资组合包涵广泛的跨境投资项目,而公司亦致力发掘新的投资机遇。黑桃资本的投资策略旨在广泛覆盖地理区域及行业,同时保持多元化资产类别,投资组合包括股票、债券、医疗科技、文化产业、绿色能源、房地产和上市前投资的项目。于2021年7月,由黑桃资本附属公司为作为发起人的特殊目的收购公司Black Spade Acquisition Co(纽交所股份代号:BSAQ)于纽约证券交易所挂牌上市。有关卓智医疗控股有限公司卓智医疗控股有限公司是香港最大的专业医学扫描诊断集团。卓智医疗成立于2006年,现已发展成为领先的医学扫描诊断平台,并拥有多个服务点,提供全面的医学扫描诊断服务包括磁力共振 (MRI)、计算机扫描(CT Scan)、2D和3D乳房造影、超声波和X光。卓智医疗为公营及私营医疗机构提供服务,并与不同的非政府机构建立合作伙伴关系,目的是使公众能够获得医学扫描诊断服务。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
碧瑶中标食环署湾仔及旺角区废物收集服务合约价值港币1.4亿 ACN Newswire

碧瑶中标食环署湾仔及旺角区废物收集服务合约价值港币1.4亿

HONG KONG, Jun 14, 2022 - (亚太商讯 via SEAPRWire.com) - 碧瑶绿色集团有限公司(「碧瑶」或「集团」; 股份编号:01397. HK)欣然宣布,集团获得香港特别行政区政府食物环境卫生署(「食环署」)批出两份为期五年的服务合约,总额合共约1.4亿港元,分别由2022年6月1日起于旺角区及2022年7月1日起于湾仔区提供废物收集服务。连同上述两区,碧瑶的废物收集服务将拓展至全港共五区,服务总人口约150万人,为本港废物管理市场中的领导者之一。为配合政府的「智慧城市蓝图」及「香港气候行动蓝图2050」,碧瑶于废物管理服务中全面引入各种创新科技,以提升香港人的生活质素。例如于集团的废物收集车辆上安装智能消毒喷雾装置及创新除臭管理系统,以达致最高的卫生标准。 另一方面,集团运用全球定位系统(GPS)、驾驶记录系统、手机应用程序以及二维码等不同系统,以实时管理、记录及跟进废物收集车队的情况,以确保车队的营运效率及服务质素达至最高水平。碧瑶视可持续发展为首要任务,于上述食环署合约,主动引入电动汽车,以减少碳排放及改善空气质素。与此同时,集团更引入低地台废物收集车,确保道路安全。碧瑶主席吴永康先生表示:「碧瑶欣然获得两份食环署服务合约,足証社会对集团一直以来努力改善社区环境的肯定。碧瑶的员工本身就住在所服务的社区,当然为提供最佳服务,不遗余力。为香港创建一个健康社区,高效的废物管理绝不可或缺。集团的员工一直努力不懈,以确保都市废物能得到积极、适时和专业处理。碧瑶作为香港最大及备受敬重的综合环境服务集团之一,深信我们的服务对改善香港生活环境,能起重大作用。集团亦一直致力探索各种创新绿色科技,进一步推动香港成为一个更清洁、更环保及更可持续发展的城市。」碧瑶绿色集团简介:碧瑶绿色集团(股份编号:01397) 成立于1980年,是香港最大和最受敬重的综合环境服务集团之一,提供环卫星保洁、资源回收、循环再造、废物管理、绿色科技、有机肥料及动物饲料生产、园艺绿化工程及害虫防治等。集团为不同领域的客户提供服务,包括政府部门、各大机构和跨国企业。集团努力不懈地提升环境、社会和管治(ESG)的表现,以推进集团的可持续发展,以实现将香港推动成为更清洁、更绿色、更健康城市的愿景。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More